ARTICLE | Company News
Visible Genetics, Abbott in genotyping deal
July 16, 2001 7:00 AM UTC
In two clinical trials involving ABT's Kaletra protease inhibitor, VGIN will perform genotype analyses to identify HIV resistance using its Trugene HIV-1 genotyping system. VGIN can include the data i...